HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive: However, paradoxically, treatment with various HDAC inhibitors, which induce acetylation, also result in decreased survival of CML cells (Nimmanapalli et al., 2003a,b; Fiskus et al., 2006a,b).